Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 8, 2022
(Exact name of registrant as specified in its charter)

(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)

530 Old Whitfield Street
Guilford, Connecticut
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (203) 458-7100

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which
Class A common stock, par value $0.0001 per share
  QSI   The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
  QSIAW   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01
Regulation FD Disclosure.

From time to time, Quantum-Si Incorporated (the “Company”) presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On March 8, 2022, the Company gave a presentation at the 42nd Annual Cowen Health Care Conference. The presentation slides and a replay of the webcast is available on the “Investors” section of the Company’s website at https://ir.quantum-si.com. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01.
Financial Statements and Exhibits.
(d)          Exhibits.
Corporate Presentation of Quantum-Si Incorporated dated March 8, 2022.
Cover Page Interactive Data File (embedded within the Inline XBRL document).


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Claudia Drayton
Claudia Drayton
Chief Financial Officer
Date: March 8, 2022

Exhibit 99.1

 Quantum-Si  Investor Update  March 8 2022 

 Disclaimer  This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; our ongoing leadership transition; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following anticipated commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties discussed in the “Risk Factors” section of the Company’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC), and risks described in other filings the Company may make with the SEC in the future. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. 

 “I start each company to improve the life of somebody I love.”   Dr. Jonathan M. RothbergFounder & ChairmanInterim CEOQuantum-Si  QUANTUM SI  3 

 We build ecosystems toDigitize MedicineApply Deep Learning Enabled AIDemocratize Healthcare     4 

 We harness the power of semiconductor technology for   Speed  Simplicity  Scale  QUANTUM SI  5 

 90%   Most diseases are linked to dysfunctional proteins, as humans share 99.9% of DNA sequence.   85% of the human proteome is currently undrugged2, potential for game changing drug development.   of FDA-approved drugs target a protein   Source(s): 1. The Human Proteome Tissue Atlas - Druggable Proteome, 2015, The Human Protein Atlas Project2. A Quest to Drug the Undruggable, June 2018, Chemical & Engineering News  QUANTUM SI  6  Protein modifications are real-time indicators of health and disease, making them ideal markers for disease, drug response and health. 

 Current tools limit the use of protein biomarkers. Routine tests for Serum & Cerebrospinal Fluid (CSF) are constrained by number of analytes they can look at, sensitivity, and specificity.    thousands   research papers found   of protein biomarkers  100   yet less than   are routinely used in clinic1   150,000   QUANTUM SI  7  Source: 1.https://www.nature.com/articles/469156a 

   We Understand Digital Technologies Transform Markets  Microarray  DNA Sequencing      Analog  Digital    Protein Sequencing  Digital  Affinity Arrays  20k genes  200k transcripts  1M+ proteoforms  1 cell  Analog   

   Analog Affinity-based Approaches      Digital Sequencing-based Approaches        Identify known proteins       Decode Novel Sequences         SomaLogic  Olink  Nautilus  Quantum-Si  Encodia  Erisyon  Detection Method  Aptamers  Antibodies  Aptamers / Antibodies  Direct Real-Time   N-terminal binding + Edman degradation with NGS readout  Side chain labeling + Edman degradation with scanning  Instrument Costs  $$ - $$$(NGS Optional)  $ - $$$(NGS Optional)  $$$  $  $$ - $$$(NGS Required)  $$  Run Costs  $$ - $$$(NGS Optional)  $ - $$$(NGS Optional)  $$ - $$$  $  $$ - $$$ (NGS Required)  $$  AA Sequencing  NO  NO  NO  YES  LIMITED  LIMITED  Read Length Scaling  N/A  N/A  N/A  HIGH  LOW  LOW  PTM Detection  ?(Affinity Reagent)  ?(Affinity Reagent)  ?(Affinity Reagent)  SCALABLE  ?  ?  Notes  *Can’t differentiate between proteoforms unless they create a specific affinity reagent       Kinetics for amino acids & PTMs  NGS erases quantitative information  Harsh acidic environment limits utility  Analog vs Digital Approaches to Proteomics 

 Q-Si End-to-End Proteomics Solution   CARBON: $20,000Cartridge based sample preparation for Protein or DNA  PLATINUM: $70,000Real Time, Massively Parallel, Single Molecule  CONSUMABLES: $1,000/Each Library Prep & Protein Sequencing  Sample Prep  Sequencing & Cloud Analysis  Kitted Reagents & Chips     

 Results  Library Prep  Loading  Enrichment  Sequencing  Analyze sequence to discover new proteins, decode amino acid sequence & post-translational modifications  Sequence by recognizing the amino acid at the end, removing it, and recognizing the next one  Immobilize peptides in wells (2 Million wells per chip)  Digest and add Linker for bar-coding and loading (multiple samples or single cell proteomics)  Workflow for Q-Si Next-Gen Protein Sequencing™  Enrich proteins of interest                                      F  L  Y  I                          AFVILVEDSDDFRSEFKSDDKLIVFFDSEFRELFDERKSLSAWDSELKSELKILCSF  AFVILVEDSDDFRSEFKSDDKLIVFFDSEFRELFDERKSLSAWDSELKSELKILCSF  AFVILVEDSDDFRSEFKSDDKLIVFFDSEFRELFDERKSLSAWDSELKSELKILCSF 

   World’s First Massively Parallel Next-Gen Protein SequencingTM   Additional details are available in our preprint on bioRxiv         Library Preparation and Loading  Protein Sequencing  QUANTUM-SI 

   The Magic Enabling Broad Coverage of the Proteome  While each protein is unique, the enzyme machines we engineer (aminopeptidases) have evolved to make all peptides behave the same in our system!  QUANTUM SI  13 

                           Fits into existing proteomic workflow.   Universal Process for Protein Sequencing  Cells  Sub-cellular Fractionations  Chromatography  IP/Co-IP  Gel  Hormones  Peptide Antigens   Panels of Interest   Single Protein/Complex   C-Functionalization  Digestion | K-Functionalization    Post-Translational Modifications   Amino Acid Sequence   Protein Identification  Serum  Tissue    Spinal Fluid   

 500+ Advanced Leads by Workflow  Estimates based on 50% IP/Co-IP, 30% Chromatography, and 20% Gel of 500+ advanced leads 

 Collect Cerebrospinal Fluid (CSF)    Biological & Clinical Challenge:Less than 1% of Alzheimer’s caused by an inherited single gene.Somatic mutations - mutations accumulated over a lifetime.Technical Challenge:Source of mutation not known.Mass spec is expensive, inconsistent, and often not sensitive enough.Solution:Sequencing of the peptides to identify changes in amino acid sequence.   Alzheimer’s Risk Assessment  How can you test for early onset Disease?      Workflow  CSF  Library Prep  Loading  Sequencing  Results    LVFF  LVLF  Enrich Beta Amyloid from CSF  Healthy  Plaque forming  Sequence  16 

 Metabolic Disease     How can you identify modification of critical peptide hormones?  Biological & Clinical Challenge:Heterogeneous populations of variants.Technical Challenge:Accuracy of detection for small mass differences is not consistent by mass spec.Sensitivity challenging for less abundant modifications.Solution:Immunoprecipitation and Sequencing of the peptides to identify point mutations.  GFFYTPKWT Insulin Peptide  GFLYTPKHyperproinsulinemia Insulin Peptide  VFFYTPKPNDM Insulin Peptide  Sequence   Insulin  Tissue / Biofluid  Library Prep  Loading  Sequencing  Results        No action  Proinsulin/Insulin ratio monitoring,Insulin resistance improvement therapy (pioglitazone)  Insulin supplement therapy  Enrich Insulin from blood  17 

 Drug Development     Workflow  Cell Line  Library Prep  Loading  Sequencing  Results                            How do you identify proteins that interact with target proteins of interest?  Biological & Clinical Challenge:New proteins in my pathway?How does the complex change in disease?Technical Challenge:Routine, robust, scalable, sensitive tools to discover new proteins and post-translational modifications.Solution:Peptide sequencing to discover new proteins.Comparisons between samples to identify new post-translational modifications.  (-) AKT Phosphorylation  Add drug candidate to cell culture  Co-Immunoprecipitation  (+) AKT Phosphorylation        F  L  I  pY  Drug response  No drug response  Sequence  18 

 Single Molecule, Single Atom Detection     1,000,000+ Protein Variations!  Biological & Clinical Challenge:A protein’s modifications determine its function.What biomarkers can we discover?Technical Challenge:Impossible technical challenge to generate affinity reagents to ALL PTMs in context (over 1 million).Solution:Q-Si detects modifications without a priori knowledge.Powerful new method for comparing disease & treatment states to find biomarkers.Kinetics enable the detection of post-translational modifications; oxidation, phosphorylation, glycosylation (in the penultimate amino acids).           L0.93 s   M0.17 s     L0.28 s  No a priori knowledge needed to detect new biological markers.  The oxidation of the penultimate residue is detected by a reduction in the average pulse duration of the N-terminal recognizer (as well as by the blocking of recognition of methionine when it becomes the N-terminal amino acid, as sequencing proceeds).  19  Biological Challenge:Proteoforms are a potentially rich source of clinically relevant information and new biomarkersTechnical Challenge:Open ended questions, so can’t develop affinity reagents at start.Solution:Q-Si Sequencing is powerful for comparing biological states (eg disease & treatment) for proteoform-based biomarkers.Rich untapped biomarker opportunity. 

   Buy $200k benchtop MALDI?Send out sample to Mass Spec core?  Can do a Western.But no Antibody identifies it or explains the difference.    Sequence with convenient,easy to own benchtop box  Workflow  Gel Band  Library Prep  Loading  Sequencing  Results        Sequence Proteins Like we Sequence DNA  Biological & Clinical Challenge:What is this protein?How is it modified?Technical Challenge:Weeks waiting for answers from a mass spec core facility.Antibodies don’t provide new insights.Solution:Discover new proteins of interest.Identify new protein variations and post-translational modification.   Proteomics Core on Your Benchtop  Gel purified protein What is the second band?    20 

   Future of Therapy Selection  Profiling Cancers to Guide Therapy     Workflow  Clinical Challenge:Survival depends on early correct therapy selection and modifications of treatment regimens.Technical Challenge:Genetic tests detect chromosomal aberrations, not protein alterations.Disease instability requires frequent testing & new understanding.Solution:Q-Si Sequencing enables biomarkers select therapy.  Tissue / Biofluid  Library Prep  Loading  Sequencing  Results        Immunoprecipitate 5-10 proteins from biopsy  Chemotherapy   Sequence   Radiation therapy        F  L  Y  I  MDM2  P16 kinase  VEGFR  p53  MTA1  21 

   Enabling Personalized Medicine  Identify Antigens for Personalized Immunotherapy or to Understand Infection     Workflow  Clinical Challenge:Highly diverse peptides of unknown origin.Need to identify modifications.Technical Challenge:Peptides missed by mass specRelevant neoantigens or antigenic pathogens relatively low abundant.Solution:Q-Si sequencing to identify antigen targets.Understanding of new Covid Variants.  Tissue / Biofluid  Library Prep  Loading  Sequencing  Results        Isolate antigen presenting cells   Elute MHC peptides              Assess infection (long-haul COVID)   Sequence   Synthesize personal cancer vaccine         F  L  Y  I  22 

 Goals for Commercial Launch  ~70% loading of proteome after library prep into 5 to 25 amino acid long peptides200,000+ reads per run, with 10 to 20 reads for each high confidence call5 to 50+ proteins over 3 or 4 logs concentration range  

 Roadmap for Customer Adoption & Growth       Research DrivenAdoption   Clinical Use to ExpandUser Base & Increase Utilization   2021  2025  Expand Coverage of Proteome  ✅ Scaled Production/Supply Chain  Early Access  UnderstandKey Influencers  Initial Launch2022  Product Updates2023  Portfolio Expansion2024  Consumables  Devices 

 to fund work through 2024    ~$470 M   With team members that invented and commercialized the first Next Generation DNA Sequencing and put DNA sequencing on a Semiconductor chip, we are well positioned to launch the World’s First Next-Generation Protein Sequencing  Experienced   team of  150+  QUANTUM SI  25 

 Oncology drove Next Generation DNA Sequencing  Immunology, Immuno-oncology & Infectious Disease will drive Next-Gen Protein Sequencing™  QUANTUM SI  26  Catalyst for Success 

 The firstto bring Next-Gen DNA Sequencing to market       The visionto bring Moore’s Law to DNA Sequencing  The teamto bring Next-Gen Protein Sequencing™ to the world